Literature DB >> 11832772

p53 and microvessel density in primary resection specimens of superficial bladder cancer.

Frank Reiher1, Ozden Ozer, Michael Pins, Borko D Jovanovic, Scott Eggener, Steven C Campbell.   

Abstract

PURPOSE: p53 Regulates angiogenesis in fibrosarcoma and correlative studies suggest a similar role for muscle invasive bladder cancer. We evaluated the associations of p53 status and microvessel density with pathological features and clinical outcomes in a large population of patients with superficial bladder cancer. In addition, we assessed the correlation of p53 status with microvessel density, which would suggest the regulation of angiogenesis by p53.
MATERIALS AND METHODS: We stained 84 primary bladder resection specimens, including 55 stage pTa, 29 stage pT1, 27 grade 1, 35 grade 2 and 22 grade 3 samples, for p53, CD31 and CD34. The relationships of p53 or microvessel density and tumor stage-grade or clinical recurrence-progression were analyzed by analysis of variance and pairwise comparison analysis for least significant difference, and Pearson correlation coefficients. Only patients with no previous biopsy were included in analysis to preclude interference by granulation tissue related neovascularization. The 4 samples with significant inflammation were also excluded from study.
RESULTS: At a mean followup of 33 months (range 1 to 93) 34 of 84 patients (40.4%) experienced 1 or more tumor recurrences and 10 (11.9%) had stage and/or grade progression. Statistically significant associations were observed of p53 immunostaining and microvessel density with tumor stage and grade (p <0.05). However, the association of p53 status with microvessel density was weak and not statistically significant. Similar results were observed for the CD31 and CD34 based estimates of microvessel density. Neither p53 status nor microvessel density correlated with recurrence or progression.
CONCLUSIONS: Our study confirms the strong association of p53 and microvessel density with the well established prognostic factors of grade and stage in superficial bladder cancer, supporting other evidence of an important role for p53 and angiogenesis in the tumor biology of this disease. However, our data argue against a primary role of p53 in the regulation of angiogenesis in superficial bladder cancer. This study, which to our knowledge is the first to focus on primary resection specimens, suggests that other genetic or environmental factors may contribute to the regulation of angiogenesis in superficial bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832772

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non HCC prevalent area in China.

Authors:  Hu Liu; Yuan Wang; Qing Zhou; Shu-Yu Gui; Xu Li
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

2.  Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy.

Authors:  Yadong Li; Jinsong Zhang
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

3.  Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer.

Authors:  George E Theodoropoulos; Andreas C Lazaris; Vasilios E Theodoropoulos; Kalliopi Papatheodosiou; Maria Gazouli; John Bramis; Efstratios Patsouris; Dimitrios Panoussopoulos
Journal:  Int J Colorectal Dis       Date:  2005-07-29       Impact factor: 2.571

4.  The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.

Authors:  M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

5.  Prognostic significance of angiogenesis in superficial bladder cancer.

Authors:  N E Stavropoulos; C Bouropoulos; I E Ioachim; M Michael; K Hastazeris; I Tsimaris; D Kalogeras; Z Liamis; S Stefanaki; N I Agnantis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.